Skip to main content
Department of Pharmaceutical Organic Chemistry

Research

Our researches Plan:

1- Development, study in depth of pharmaceutical organic chemistry and illustration of its synthetic, mechanistic, and industrial applications.

2- Design and synthesis of different classes of compounds such as: Triazoles, benzimidazoles, piperazinedione and thiadiazine derivatives and others A special focus on xanthine and pyridazinone derivatives

3- Structural elucidation of the target compounds utilizing: IR,1H-NMR, MS in addition to elemental analysis Optical Rotation

4- Biological screening: Antimicrobial: antibacterial, antifungal and antituberculosis in addition to anthlemintic activity. Anti-inflammatory, analgesic, antipyretic activities and ulcerogenicity determination. Cardiotonic and hypotensive activities. Hypoglycemic activity. Anticonvulsant activity.

5- Other titles in consideration: Synthesis of new dendimers of potential biological activity. Applications of photochemical reactions for synthesis of certain organic compounds of potential biological activity. Synthesis of some antineurodegenerative compounds. Synthesis of certain nucleosides of potential biological activity. Synthesis of certain adenine derivatives of possible antiviral activity.

# Title Research Year
71 Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation 2022
72 New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization 2022
73 Synthesis, Characterization, and Antifungal Activity of Some New Thieno[2,3-b]pyridines Incorporating Quinazoline or Benzimidazole Moiety 2021
74 Development of new hetero‑steroid hybrids with antiproliferative activity against MCF‑7 breast cancer cells 2021
75 Novel 1,2,4-oxadiazole/pyrrolidine hybrids as DNA gyrase and Topoisomerase IV inhibitors with potential antibacterial activity 2021
76 . Synthesis, Characterization and Photophysical Properties of Some New Thieno[2,3-b]pyridines bearing phenylethenyl moiety 2021
77 A first-in-class anticancer dual HDAC2/FAK inhibitors ‎bearing hydroxamates/benzamides capped by ‎pyridinyl-1,2,4-triazoles 2021
78 New quinoline/1,2,4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study 2021
79 FAK inhibitors as promising anticancer target: Present ‎and future directions 2021
80 Structure-based design, synthesis, and biological evaluation of novel piperine–resveratrol hybrids as antiproliferative agents targeting SIRT-2 2021